(Q37078178)

English

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial

scientific article published on 21 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial (English)

1 reference

Europe PubMed Central

18 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

fatty liver disease

0 references

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

author name string

Mohsen Razavizade

1

1 reference

Europe PubMed Central

18 August 2017

Raika Jamali

2

1 reference

Europe PubMed Central

18 August 2017

Abbas Arj

3

1 reference

Europe PubMed Central

18 August 2017

Seyyed Mohammad Matini

4

1 reference

Europe PubMed Central

18 August 2017

Alireza Moraveji

5

1 reference

Europe PubMed Central

18 August 2017

Effat Taherkhani

6

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

21 May 2013

1 reference

Europe PubMed Central

18 August 2017

Hepatitis Monthly

1 reference

Europe PubMed Central

18 August 2017

13

1 reference

Europe PubMed Central

18 August 2017

5

1 reference

Europe PubMed Central

18 August 2017

e9270

1 reference

Europe PubMed Central

18 August 2017

Predictive factors for ultrasonographic grading of nonalcoholic Fatty liver disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Hepatocellular carcinoma in pakistan: where do we stand?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Metformin therapy and clinical uses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Use and abuse of HOMA modeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

29 September 2017

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

27 June 2018

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

27 June 2018

Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Epidemiology of fatty liver in an islander population of China: a population-based case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Metformin in non-alcoholic steatohepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736624

4 September 2018

Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23930133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23930133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/23930133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5812/HEPATMON.9270

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37078178&oldid=1682213570"